A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Irinotecan (Primary) ; Sirolimus (Primary) ; Temozolomide (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 27 Nov 2017 Status changed from active, no longer recruiting to recruiting.
- 16 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 15 Sep 2017 Status changed from not yet recruiting to recruiting.